Delphi consensus on recommendations for the clinical management of Ph+ acute lymphoblastic leukemia patients
- 2023, Volume 42 - Number 1
- Published: July 14, 2023
Delphi consensus on recommendations for the clinical management of Ph+ acute lymphoblastic leukemia patients
Josep M. Ribera 1, M.ª Teresa Gómez-Casares 2, Rosa Ayala-Díaz 3, Margarida Coucelo 4, Pau Montesinos 5, Dolors Colomer 6, Mayte Olave 7, Pere Barba 8, Mi Kwon 9, Fernanda M. Trigo 10, Jordi Esteve 11, Arancha Bermúdez 12, Natalia Alonso 13, Josefina Serrano 14, José González-Campos 15, Ramón García-Sanz 16
1 Servicio de Hematología, Institut Català d’Oncologia, Hospital Germans Trias i Pujol, Josep Carreras Research Institute, Universitat Autònoma de Barcelona, Barcelona, España; 2 Laboratorio de Biología Molecular, Servicio de Hematología, Hospital Universitario de Gran Canaria Doctor Negrín, Las Palmas, España; 3 Servicio de Hematología, Hospital Universitario 12 de Octubre, Madrid, España; 4 Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal; 5 Departamento de Hematología y Hemoterapia, Hospital Universitario de La Fe, Valencia, España; 6 Sección de Hematopatología, Hospital Clínic de Barcelona, Barcelona, España; 7 Hospital Clínico Lozano Blesa, Zaragoza, España; 8 Hospital Universitari Vall d’Hebron, Barcelona, España; 9 5Hospital Gregorio Marañon, Madrid, España; 10 Centro Hospitalar Universitario de São João, Porto, Portugal; 11 Servei d’Hematologia, Hospital Clínic i Provincial de Barcelona, Barcelona, España; 12 Hospital Universitario Marqués de Valdecilla, Santander, España; 13 Hospital Clínico Universitario de Santiago, A Coruña, España; 14 Departamento de Hematología y Hemoterapia, Hospital Quirón Salud Córdoba, Córdoba, España; 15 Hospital Universitario Virgen del Rocío, Sevilla, España; 16 Servicio de Hematología, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, España
Josep M. Ribera, M.ª Teresa Gómez-Casares, Rosa Ayala-Díaz, Margarida Coucelo, Pau Montesinos, Dolors Colomer, Mayte Olave, Pere Barba, Mi Kwon, Fernanda M. Trigo, Jordi Esteve, Arancha Bermúdez, Natalia Alonso, Josefina Serrano, José González-Campos, Ramón García-Sanz
La información completa de afiliaciones y autor de correspondencia está disponible en la versión original en PDF.
*Correspondence: Arancha Bermúdez, Email not available
Summary
Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) is a disease with special features that give it a grim prognosis. The recent development of new laboratory techniques with diagnostic or therapeutic implications and the appearance of different generations of tyrosine kinase inhibitors have improved the management of this disease significantly and had a positive impact on its prognosis. To analyze this transformation appropriately, a comprehensive review of the evidence published to this day has been conducted to establish the body of scientific knowledge in this area. Afterwards, a list of recommendations applicable to diagnosis, treatment, and follow-up of Ph+ ALL patients were defined. The recommendations issued by the authors were evaluated by a large panel of experts. This document includes a brief update on the knowledge on Ph+ ALL, and a selection of recommendations agreed by experts from Spain and Portugal. These were considered especially relevant in the clinical management of adult patients with Ph+ ALL based on the technological advances in this area and the therapies currently available.
Keywords: Acute lymphoblastic leukemia. Philadelphia chromosome. Measurable residual disease. Mutational analysis. Tyrosine kinase inhibitors. Allogeneic stem cell transplant.
